By signing the potential $548.8 million deal for the oral, small-molecule glucagon receptor antagonist LGD-6972 with Ligand Pharmaceuticals Inc., Roivant Sciences Inc. brings aboard a type 2 diabetes candidate that "should surpass blockbuster status" if approved, in the view of one analyst.